Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Harpoon closes $15mm Series A

Executive Summary

Harpoon Therapeutics Inc. (oncology) raised $15mm in its Series A round from affiliates of MPM Capital and the UBS Oncology Impact Fund. Harpoon was formed last year and is developing cancer therapies based on its TriTAC (Tri-specific T cell Activating Construct) platform. TriTAC antibodies bind simultaneously to cancer cells and a patient’s own T-cells, causing the T-cells to release toxins that destroy the tumor.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies